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OBJECTIVES We sought to define the therapeutic dose range of levosimendan in patients with New York
Heart Association class II-IV heart failure of ischemic origin.
BACKGROUND Levosimendan is a calcium sensitizer for treatment of acute decompensated heart failure.
METHODS A double-blind, placebo-controlled, randomized, multicenter, parallel-group study included
151 adult patients. Levosimendan was given as a 10-min intravenous bolus of 3, 6, 12, 24 or
36 mg/kg, followed by a 24-h infusion of 0.05, 0.1, 0.2, 0.4 or 0.6 mg/kg/min, respectively.
Dobutamine, for comparative purposes, was given as an open-label infusion (6 mg/kg/min).
The primary efficacy variable was the proportion of patients achieving in each treatment group
at least one of the following: 1) a $15% increase in stroke volume (SV) at 23 h to 24 h; 2)
a $25% decrease in pulmonary capillary wedge pressure (PCWP) (and $4 mm Hg) at 23 h
to 24 h; 3) a $40% increase in cardiac output (CO) (with change in heart rate [HR] ,20%);
4) a $50% decrease in PCWP during two consecutive measurements.
RESULTS The response rate to levosimendan ranged from 50% at the lowest dose to 88% at the highest
dose (compared with placebo 14%, dobutamine 70%). A dose-response relationship was
demonstrated for levosimendan on increases in CO and SV, and reductions in PCWP during
the infusion (for all, p # 0.001). Headache (9%), nausea (5%) and hypotension (5%) were the
most frequently reported adverse events at higher dosages.
CONCLUSIONS Dosing of levosimendan with a 10-min bolus of 6 to 24 mg/kg followed by an infusion of 0.05
to 0.2 mg/kg/min is well tolerated and leads to favorable hemodynamic effects. (J Am Coll
Cardiol 2000;36:1903–12) © 2000 by the American College of Cardiology
Intravenous inotropic therapy is indicated to correct the
hemodynamic disturbances encountered in end-stage con-
gestive heart failure (CHF), in the management of acute
exacerbations of chronic CHF and as a “bridge” to heart
transplantation (1). Drugs currently used for these purposes
include the beta-agonist inotropes, such as dobutamine,
and phosphodiesterase inhibitors such as milrinone. The
positive inotropic actions of these agents are based on
increased intracellular calcium concentrations that may en-
hance myocardial energy consumption and arrhythmias. In
addition, the use of beta-mimetics is limited by tachyphy-
laxis. Short-term parenteral use of beta-agonists or phos-
phodiesterase inhibitors improves hemodynamics in pa-
tients with advanced CHF, but the longer term oral use of
several of these drugs has been associated with worsened
mortality (2,3).
Increasing myocyte sensitivity to calcium is an alternative
basis for positive inotropy (4). This approach, in theory, has
the advantage that the contractile performance of the failing
heart can be enhanced with little increase in total myocardial
energy demand and with a decreased potential for arrhyth-
mias (5,6). Levosimendan promotes inotropy by stabilizing
troponin C in a configuration that enhances the calcium
sensitivity of cardiac myofilaments (7–9). Unlike other
calcium sensitizers, this effect of levosimendan is shown to
be dependent on the concentration of intracellular ionized
calcium. As a result, levosimendan is shown to increase
cardiac contractile force during systole but not to impair
ventricular relaxation (10,11). Furthermore, levosimendan
opens adenosine triphosphate-dependent potassium chan-
nels, leading to vasodilatation (12,13). Levosimendan is a
selective inhibitor of phosphodiesterase III in vitro, but at
therapeutic doses its inotropic effects are independent of
cAMP (14).
We report the results of a study conducted to determine
the therapeutic dose range of intravenous levosimendan in
patients with New York Heart Association (NYHA) func-
tional class II–IV heart failure. Participation in the study
was restricted to patients with heart failure of ischemic
etiology, in order to detect any potential of levosimendan to
induce myocardial ischemia. Dobutamine was used as a
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positive control in this placebo-controlled randomized
study.
METHODS
Patients. A group of 151 patients with stable CHF
(NYHA class II or IV) of ischemic origin was recruited
from a total of 12 centers in Finland, Sweden, Germany and
The Netherlands between April 1994 and October 1996.
Participating patients were 18 to 85 years old, had left
ventricular ejection fraction ,40% as determined by echo-
cardiography (according to Simpson’s rule or the area-
length method), left ventricular angiography or multiple-
gated acquisition of left ventricular function by nuclear
imaging, were in sinus rhythm and weighed not more than
110 kg with a body-mass index not exceeding 35 kg/m2.
Patients were required to have had unchanged medication
for at least one week before enrollment and not have an
acute need for intravenous inotropics.
The main exclusion criteria were myocardial infarction,
stroke or hospitalization for any disabling disease other than
CHF (including angina pectoris) during the three months
before enrollment; systolic blood pressure ,100 mm Hg or
.200 mm Hg; recent symptomatic ventricular tachyar-
rhythmia; heart rate (HR) ,50 or .100 beats/min at rest;
second- or third-degree atrioventricular block; renal insuf-
ficiency (serum creatinine .150 mmol/L); abnormal liver
function (serum alanine transaminase levels more than twice
the upper reference limit); chronic pulmonary disease;
hemodynamically significant obstructive valvular disease or
use of amlodipine or class IC antiarrhythmics. Women with
childbearing potential were ineligible.
Patients were in a stable condition at rest without the use
of long-acting nitrates. To standardize concomitant medi-
cations, it was recommended that all angiotensin-converting
enzyme inhibitors be changed to enalapril (5 to 20 mg daily)
one week before the study day. Oral nitrates were withheld
during the study day. Patients were allowed to take beta-
blockers during the study at half the dose used previously.
Calcium antagonists (amlodipine was an exclusion criterion)
were withheld one week before the study day. Angiotensin-
converting enzyme inhibitors and beta-blockers were pre-
ferred if a patient required anti-ischemic or antihypertensive
therapy. Diuretic dose was adjusted at the prestudy visit and
kept stable. Digitalis glycosides were not taken during the
morning of the study day, but discontinuation was consid-
ered unethical because many CHF patients have atrial
fibrillation.
After approximately 25 patients had entered the study it
became apparent that the clinical eligibility criteria favored
patients with low pulmonary capillary wedge pressures
(PCWPs). The protocol was amended to permit recruit-
ment of patients with class IV heart failure; the acceptable
left ventricular ejection fraction was lowered to 35% and the
requirement of sinus rhythm was abolished.
Study procedure. Pretreatment hemodynamic parameters
were measured 2 h after the introduction of a Swan–Ganz
catheter and 30 min before starting study medication
(230 min) with repeat measurements 20 and 10 min before
starting treatment (220 and 210 min). Baseline level was
taken as the mean of the measurements at 220 and
210 min. Infusion of the study drug was then started via the
sheath of the Swan–Ganz catheter by a calibrated infusion
pump to ensure as stable a baseline as possible (15). Any
other spontaneous changes during infusion were encoun-
tered by large control groups.
Patients were randomized to receive double-blind levosi-
mendan (SimdaxTM, Orion Pharma, Finland), double-blind
placebo, open-label vehicle or an open-label infusion of
dobutamine (DobutrexTM, Eli Lilly, Indianapolis, Indiana),
which was given at a constant rate of 6 mg/kg/min without
a loading dose. Levosimendan treatment was started with
loading doses of 3, 6, 12, 24 or 36 mg/kg administered in
10 min, followed by infusion of levosimendan at rates of
0.05, 0.1, 0.2, 0.4 or 0.6 mg/kg/min, respectively. For
pharmaceutical reasons, the double-blind placebo contained
less ethanol than levosimendan. Therefore, a separate eth-
anol vehicle group (see earlier) was included as an additional
negative control group. Because dobutamine was given
without a bolus dose, this treatment was not blinded.
Study treatment was stopped for 1 h and then resumed at
half the previous rate if any of the following conditions were
met: HR reduced to ,50 beats/min or increased .20%
from baseline for 10 consecutive min; systolic blood pressure
reduced to ,90 mm Hg for 5 min or symptomatic hypo-
tension; cardiac output (CO) increased by .40% compared
with baseline; PCWP reduced by $50% from baseline in
two consecutive measurements; or the development of
adverse events related to use of study medication. In
addition, study treatment was discontinued if symptomatic
ischemia (angina with an ST-segment depression .0.2 mV
in precordial leads [Marquette Electronics, Series 8000;
version 5.80]), sustained ventricular tachycardia (.150
beats/min for 30 s) or clinically more severe arrhythmia,
second- or third-degree atrioventricular block, or any severe
adverse event was recorded.
Right atrial pressure (RAP), pulmonary artery pressure
(PAP) and PCWP were measured at 0 min (immediately
after the bolus dose) and 30 min, at 1, 2, 4, 8, 23, 23.5 and
24 h from the start of the infusion, and at 1 and 2 h after
Abbreviations and Acronyms
CO 5 cardiac output
CHF 5 congestive heart failure
ECG 5 electrocardiogram
HR 5 heart rate
MBP 5 mean blood pressure
NYHA 5 New York Heart Association
PAP 5 pulmonary artery pressure
PCWP 5 pulmonary capillary wedge pressures
RAP 5 right atrial pressure
SV 5 stroke volume
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completion of the infusion. CO was measured in triplicate
by the thermodilution technique at the same times as the
hemodynamic recordings were measured, and HR was
measured from ECG recordings of six consecutive QRS
complexes. Stroke volume (SV) was calculated from the CO
and HR. Systolic and diastolic blood pressures (Korotkoff
phase V) were measured to an accuracy of 2 mm Hg, always
from the same arm, by auscultation with an automatic or
semiautomatic manometer with the patient in the supine
position; mean blood pressure (MBP) was derived from
these measurements. The ECG was recorded continuously
throughout the study day via the V2 and V5 precordial leads.
Blood samples for the determination of plasma epineph-
rine, norepinephrine, renin and atrial natriuretic peptide
levels were taken immediately before infusion, after 30 min
and 8 h of infusion, and 2 h postinfusion. Samples were
stored at 270°C until use, when they were prepared by
centrifugation (3,000 rpm 3 10 min). Catecholamines were
assayed by high-pressure liquid chromatography (ESA
Model 5100 A Coulochem with Beckman Ultrasphere
C-18 column and dihydroxybenzylamine as the assay stan-
dard) at the University of Turku, Turku, Finland. Atrial
natriuretic peptide and renin were quantified by radio-
immunoassay (Oy Medix Ab, Helsinki, Finland).
An adverse event inquiry was undertaken before the start
and after the termination of infusion. Patients were followed
up for medical examination, adverse event inquiry and the
determination of blood chemistry variables for two to nine
days after the study.
Efficacy criteria. The primary efficacy variable was the
proportion of patients in each treatment group who re-
sponded to treatment by attaining one or more of the
following four prespecified end points: 1) a $15% increase
in SV at 23 h to 24 h; 2) a $25% decrease in PCWP (and
$4 mm Hg) at 23 h to 24 h; 3) a $40% increase in CO
(with a change in HR of ,20%) leading to a reduction in
the dose of study medication at any time during the
infusion; 4) a $50% decrease in PCWP during two con-
secutive measurements leading to a reduction in the dose of
study medication at any time during the infusion. Changes
from baseline of the three hemodynamic components of this
primary end point were also analyzed.
Secondary efficacy end points included changes in directly
measured or derived hemodynamic indices (HR, PAP,
PVR, RAP, MBP and total peripheral resistance). In
addition, the following post-hoc analyses were undertaken:
patients aged ,65 years versus $65 years, PCWP ,
15 mm Hg versus $15 mm Hg, MBP , 95 mm Hg versus
$95 mm Hg, men versus women, and use versus nonuse of
beta-blockers or digitalis.
Statistical methods. The primary measure of efficacy spec-
ified in the protocol was a “responders analysis” based on a
combination of prespecified changes in CO, PCWP and
SV. All analyses were based on the intention-to-treat
principle. A last-observation-carried-forward approach was
used if hemodynamic data were missing. Ta
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The sample size calculation was based on the binomial
distribution and on the assumptions that under one of the
doses of levosimendan the response rate is at least 50% and
that of placebo 5%. In the final protocol the two-sided type
I error was set to 5% and the type II error to 10%, which
gave a group size of 19 patients with a total of 152 patients
in a balanced design of eight parallel groups.
Two analyses were conducted to test for the significance
of differences among the treatment groups: 1) tests of the
significance of differences among all eight treatment groups
using the Cochran-Mantel-Haenszel test, controlling for
center. If the overall test was significant, pairwise compar-
isons were carried out, again controlling for center; 2) tests
of the relation between dose and response for levosimendan,
using Spearman’s correlation coefficient based on six treat-
ment groups (placebo [i.e., a zero dose of levosimendan] and
five levosimendan doses).
Changes in the hemodynamic components of the primary
end point (CO, PCWP and SV) and changes in secondary
hemodynamic variables were compared across the treatment
groups using an analysis of covariance model with effects for
treatment, center and treatment-by-center interaction ad-
justed for baseline value. Changes from baseline values were
calculated as the least square means. The significance of
observed differences between treatments in the change from
baseline was evaluated by an analysis of covariance proce-
dure controlling for treatment, center and treatment-by-
center interaction and using the baseline value as a covariate.
The frequency of adverse events was compared using Fisher
exact test. Descriptive statistics were used to examine
alterations in laboratory variables during treatment. Analysis
of ECG data was based on the Cochran-Mantel-Haenszel
test, controlling for center.
Statistical significance was originally defined by an alpha-
value of 0.05 or less in two-tailed tests. An interim analysis
of the data was undertaken after 28 patients had completed
the study, however, and the protocol was modified. The
alpha-level associated with the primary end point was
therefore adjusted to 0.025. An alpha-level of 0.05 was
retained for other analyses.
Ethanol vehicle had no significant effect on any hemo-
dynamic variables studied (data not shown) and thus the
placebo and vehicle results are pooled in the major analyses.
ETHICAL CONSIDERATION. The study followed the princi-
ples of the Declaration of Helsinki of the World Medical
Assembly with amendments. The protocol was approved by
local Ethics Committees according to national regulations.
Informed written consent was obtained from all participat-
ing patients or their proxies. The study was monitored in
accordance to Good Clinical Practice guidelines in the
European Community.
RESULTS
Demographic and baseline features. Baseline characteris-
tics of the 151 patients are summarized in Tables 1 and 2.
Most of the patients (n 5 132) were male, most (n 5 147)
had class III CHF and all but one (an Asian) were
Caucasian. There were no statistically significant intergroup
differences.
Efficacy. RESPONSE RATE. Favorable hemodynamic re-
sponses to levosimendan were observed in at least 50% of
patients at all doses studied, with a clear dose-response
relationship (Fig. 1). Response rates obtained with all doses
of levosimendan studied were significantly greater than the
response rate seen with placebo (p 5 0.038 at lowest dose;
p # 0.005 at all other doses). The response rate obtained
with dobutamine (70%) was significantly greater than with
placebo (27%; p , 0.001) but did not significantly differ
from any dose of levosimendan. The response rate to
levosimendan was higher among those patients with a
baseline PCWP $15 mm Hg than in patients with a lower
PCWP (placebo-adjusted rate 86% vs. 29%; p 5 0.037). No
significant variations in response rates were discovered in
other patient subgroups.
PRINCIPAL HEMODYNAMIC INDICES. Levosimendan ex-
erted a dose-dependent effect on CO, SV and PCWP (for
all, p , 0.001 for linear dose trend) (Table 2). At 23 h to
24 h, all doses of levosimendan produced significantly larger
Table 2. Patients’ Baseline Hemodynamics and Changes After 24 h Infusion of Study Medication
Group
CO
(L/min)
DCO at
23–24 h
SV
(ml)
DSV at
23–24 h
PCWP
(mm Hg)
DPCWP
at 23–24 h
P-value for linear dose trend , 0.001 , 0.001 , 0.001
Dobutamine (n 5 20) 4.3 6 0.2 0.6 6 0.2 62 6 4 3.5 6 2.3 16 6 2 21.3 6 1.2
LS 0.6 mg/kg/min (n 5 14) 4.5 6 0.2 1.6 6 0.3 61 6 4 3.5 6 3.8 15 6 3 27.1 6 1.8
LS 0.4 mg/kg/min (n 5 23) 4.6 6 0.2 1.3 6 0.2 62 6 4 7.6 6 3.1 17 6 2 25.7 6 1.2
LS 0.2 mg/kg/min (n 5 19) 5.1 6 0.4 0.7 6 0.2 70 6 4 21.8 6 2.5 13 6 2 25.0 6 1.2
LS 0.1 mg/kg/min (n 5 23) 4.8 6 0.2 0.4 6 0.2 66 6 4 21.8 6 2.5 16 6 1 24.5 6 1.2
LS 0.05 mg/kg/min (n 5 16) 4.2 6 0.2 0.6 6 0.2 63 6 6 0.6 6 2.5 14 6 2 23.8 6 1.1
Placebo (n 5 20) 4.7 6 0.3 20.3 6 0.2 69 6 4 26.8 6 2.0 12 6 1 0.6 6 1.0
Vehicle (n 5 15) 5.2 6 0.3 20.1 6 0.2 78 6 5 24.4 6 3.2 13 6 1 20.9 6 0.8
Dosages of levosimendan refer to continuous infusion. See text for details of bolus starting doses.
CO 5 cardiac output; HR 5 heart rate; LS 5 levosimendan; MBP 5 mean blood pressure; PAP 5 pulmonary arterial pressure; PCWP 5 pulmonary capillary wedge pressure;
RAP 5 right atrial pressure; SV 5 stroke volume. Data are mean 6 SEM.
(continued on next page)
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decreases in PCWP than dobutamine (p , 0.044 for all
doses of levosimendan) and infusions of 0.4 and 0.6 mg/kg/
min produced significantly larger increases in CO (p ,
0.001 and p 5 0.003, respectively). There were no signifi-
cant differences in SV changes between the dobutamine and
levosimendan groups at any time. The CO increase is due
partly to heart rate increase (Table 2), especially with higher
dosing levels.
Secondary efficacy variables. MEASURED HEMODYNAMIC
VARIABLES. There was a significant linear relationship be-
tween levosimendan dose and the change in HR at 23 h to
24 h (p 5 0.002) (Table 2). A significant linear trend was
also demonstrated for reduction in mean PAP during
levosimendan therapy (p 5 0.002). The decrease in mean
PAP in the dobutamine group was small and did not differ
significantly from that seen with placebo (p 5 0.845).
Overall effects on RAP were small, but there was a signif-
icant linear relationship between levosimendan dose and
change in mean RAP (p 5 0.018). Levosimendan infusions
of 0.2 to 0.6 mg/kg/min produced significantly larger
decreases in mean RAP than dobutamine (p # 0.032).
DERIVED HEMODYNAMIC VARIABLES (MBP, PVR AND TOTAL
PERIPHERAL RESISTANCE). There was a significant relation
between levosimendan dose and change in MBP at 23 h to
24 h (p 5 0.012) (Table 2) even though consistent and
substantial (.5 mm Hg) decrease in MBP were recorded
only with levosimendan infusions of 0.4 mg/kg/min or
more. The reduction in MBP observed in the dobutamine
group was not statistically different from that seen with
placebo.
Total peripheral resistance response at 23 h to 24 h was
significantly related to the levosimendan dose (p , 0.001),
with reductions ranging from approximately 7% at
0.05 mg/kg/min to approximately 33% at 0.4 mg/kg/min.
Levosimendan infusions of 0.4 and 0.6 mg/kg/min pro-
duced significantly larger decreases in total peripheral resis-
tance than dobutamine infusion (p , 0.001 for both doses).
Mean change in PVR in patients treated with levosimendan
exhibited a significant linear relationship (p 5 0.005). The
mean decrease in PVR seen in the dobutamine group was
not greater than that observed in the placebo group (p 5
0.119) and was significantly smaller than with levosimendan
0.4 or 0.6 mg/kg/min (p , 0.001).
TIME-COURSE OF HEMODYNAMIC EFFECT. Additional
analyses conducted to describe fully the hemodynamic
effects of levosimendan indicated that the magnitude of the
treatment effect of levosimendan on hemodynamic indices,
notably decrease in PCWP, tended to become larger with
time (Fig. 2), whereas the effect of dobutamine was atten-
uated. The effect of levosimendan on SV was more variable
because of an excessive reduction in preload in some
patients. Linear dose-response trends were demonstrated
for levosimendan during the first 30 min of treatment,
corresponding to the phase of bolus infusion (p , 0.001 for
CO, PCWP, MBP and HR; p . 0.2 for SV), though in
pairwise comparisons the treatment effect on HR was
statistically significant only at the highest bolus studied
(36 mg/kg; p 5 0.008).
NEUROHORMONES. There were some statistically signifi-
cant changes in plasma atrial natriuretic peptide levels
during the infusion of levosimendan but no significant
changes in plasma epinephrine (Table 3). Two hours after
termination of the infusion a statistically significant increase
in norepinephrine levels was seen in patients who received
levosimendan 0.05, 0.01 and 0.6 mg/kg/min (p # 0.002).
No dose-relation was evident for the effect on norepineph-
rine. Plasma renin levels were reduced in patients who
received the lower doses of levosimendan and increased at
higher doses (0.4 or 0.6 mg/kg/min) and in those who
received dobutamine. Most of the changes were on the
order of 10% to 20% of baseline levels, though the treatment
effects of higher dose levosimendan (0.4 and 0.6 mg/kg/min)
and dobutamine were larger (;23% to 40%) and statistically
significant (p # 0.007) at 30 min and 8 h.
SAFETY EVALUATION. Overall, 29% of patients treated with
levosimendan experienced at least one adverse event during
the study day, compared with 35% of patients treated with
dobutamine and 20% of patients who received placebo. The
adverse events most frequently recorded in levosimendan-
treated patients (regardless of relation to study medication)
were headache, hypotension and nausea (n 5 9, 5 and 4,
respectively). Hypertension was reported only in the dobut-
amine group (n 5 2), and was, with tachycardia (n 5 2), the
most often recorded adverse event in dobutamine-treated
patients.
Table 2. Continued
PAP
(mm Hg)
DPAP at
23–24 h
RAP
(mm Hg)
DRAP at
23–24 h
MBP
(mm Hg)
DMBP at
23–24 h
HR
(beats/min)
DHR at
23–24 h
0.002 0.018 0.012 0.002
27 6 2 21.5 6 1.0 6.4 6 0.8 20.5 6 0.7 89 6 3 21.0 6 1.8 73 6 3 4.8 6 2.4
24 6 3 25.5 6 1.4 4.7 6 1.1 21.9 6 0.7 86 6 3 25.9 6 2.0 75 6 3 20.0 6 3.6
27 6 2 27.4 6 1.6 6.7 6 1.1 22.3 6 0.6 89 6 2 29.2 6 2.4 78 6 3 9.7 6 2.2
23 6 2 24.6 6 1.3 4.2 6 0.6 21.9 6 0.4 87 6 3 20.5 6 1.9 73 6 3 13.4 6 2.9
28 6 2 24.7 6 1.5 5.9 6 0.9 21.0 6 0.8 86 6 3 22.7 6 1.7 76 6 3 6.9 6 1.7
25 6 3 24.8 6 1.5 5.6 6 1.1 21.6 6 0.5 90 6 3 23.5 6 2.8 70 6 4 8.6 6 2.8
23 6 2 20.3 6 1.0 3.3 6 0.8 0.3 6 0.6 87 6 2 1.3 6 1.8 68 6 2 6.8 6 2.9
24 6 2 22.1 6 1.3 4.1 6 0.7 21.4 6 0.4 90 6 4 21.1 6 2.3 68 6 2 2.5 6 1.2
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Tachycardia (HR increase .20% from baseline) and
systolic blood pressure ,90 mm Hg were the two most
frequent protocol-defined dose-limiting events. Tachycar-
dia occurred in one patient who received levosimendan
0.05 mg/kg/min, in three patients in each of the 0.1 and
0.2 mg/kg/min groups, in four patients in each of the 0.4
and 0.6 mg/kg/min groups, in five patients receiving dobut-
amine and in one patient who received placebo. Low systolic
blood pressure was recorded in eight patients treated with
levosimendan (one each in the 0.1 and 0.6 mg/kg/min groups,
two in the 0.2 mg/kg/min group and four in the 0.4 mg/kg/min
group) and in one patient treated with dobutamine. Tests for
a levosimendan dose-relation to tachycardia or low systolic
blood pressure were not statistically significant (p . 0.1). Heart
rate was reduced to ,50 beats/min in one patient who received
levosimendan 0.6 mg/kg/min.
There were no deaths during the treatment day, but two
patients died during follow-up. One of these patients had
received dobutamine and had experienced a worsening of
CHF during the follow-up period. The other had received
levosimendan 0.1 mg/kg/min and died following an acute
myocardial infarction.
LABORATORY SAFETY INDICES. There were no clinically
meaningful alterations in any laboratory safety parameters
during the study day. Reductions in red blood cell count
(10% to 39%; p # 0.012), hematocrit (,10%; p # 0.011)
and hemoglobin (,10%; p # 0.01) were seen at the higher
levosimendan doses (0.2 to 0.6 mg/kg/min).
Small (;5%), but statistically significant (p , 0.05)
reductions in serum potassium occurred with the higher
doses of levosimendan. One case of hypokalemia in a patient
treated with levosimendan 0.2 mg/kg/min was reported
during the follow-up period. There were no increases in
creatinine kinase MB isoform or troponin-T in patients
who received levosimendan.
ECG RECORDINGS. The mean duration of the RR interval
was reduced by 113 6 85 ms during levosimendan treat-
ment, with evidence of a dose-effect relationship (p 5
0.002). The RR interval was also shortened in all other
treatment groups (dobutamine 29 618 ms, placebo
15617 ms; vehicle 37 614 ms). There were no substantial
effects of treatment on the QRS and PQ intervals in any
treatment group. QT interval (corrected for HR) was
increased by 15 620 ms with levosimendan 0.4 mg/kg/min
and by 45610 ms with levosimendan 0.6 mg/kg/min (p 5
0.008 for linear dose trend).
Ventricular extrasystoles and ventricular tachycardia were
recorded in the ambulatory ECG more often with dobut-
amine than with other treatments. An increased frequency
of ventricular dysrhythmias was noted at the highest dose of
levosimendan used (0.6 mg/kg/min). No differences in the
frequency of atrial arrhythmias were observed between the
groups and there was no evidence of a dose relationship.
DISCUSSION
There have been few controlled studies on prolonged
infusions of any intravenous drug indicated for the short-
Figure 1. Percentage of patients responding to levosimendan or placebo/vehicle or dobutamine (DO) by achieving predefined hemodynamic responses
(stroke volume [SV], pulmonary capillary wedge pressure [PCWP]) at 23 h to 24 h, or requiring dose reduction for specified hemodynamic changes at any
time during infusion, or having adverse dose-limiting events (DLE).
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Figure 2. Time course of levosimendan treatment effects on pulmonary capillary wedge pressure (A), stroke volume (B) and heart rate (C). Data are
placebo-adjusted means 6 SEM. Dosages of levosimendan (LS) refer to continuous infusion; see text for details of bolus starting doses. Open circle 5
levosimendan 0.05 mg/kg/min; open triangle 5 levosimendan 0.1 mg/kg/min; open square 5 levosimendan 0.2 mg/kg/min; open diamond 5
levosimendan 0.4 mg/kg/min; upside-down triangle 5 levosimendan 0.6 mg/kg/min; closed circle 5 dobutamine.
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term treatment of heart failure. Published data on the effects
of infusions continued for at least 24 h are available for
dobutamine (16), milrinone (17) and dopamine (16), but
none of those studies included a placebo group. The present
study is thus one of the largest controlled investigations of
hemodynamic effects ever carried out with an intravenous
inotrope in heart failure patients. There is a tendency of
central hemodynamic parameters to decrease with time in
studies with continuous invasive monitoring (15). Thus, a
double-blind, placebo-controlled design will assure reliable
dose efficiency comparisons and will regard the attenuation
of filling pressure by time at rest.
HEMODYNAMIC EFFECTS. The results of the present study
are consistent with previous experience with low-dose do-
butamine (16) and confirm the attenuation of hemodynamic
responses during prolonged infusion of dobutamine in
patients with severe heart failure. By contrast, bolus admin-
istration of levosimendan produced early favorable hemo-
dynamic effects that were sustained. The effects of levosi-
mendan on heart rate may be exaggerated because, for
standardization, the use of beta-blockers and digitalis gly-
cosides was limited during infusion. The hemodynamic
improvements of levosimendan were not obtained at the
expense of neurohumoral activation, which would be disad-
vantageous (18–22). In particular, levosimendan had no
marked effect on plasma norepinephrine at infusion rates up
to 0.4 mg/kg/min.
A clear and consistent relationship was observed between
levosimendan dose and hemodynamic responses. This study
indicates that the optimal dosing regimen for levosimendan
is a bolus of 6-24 mg/kg delivered in 10 min followed by
infusion at 0.05 to 0.2 mg/kg/min. Responses to levosimen-
dan were consistent across various subgroups of patients
defined post-hoc, with the exception that treatment re-
sponse was significantly greater in patients with a baseline
PCWP of more than 15 mm Hg than in those with a lower
baseline PCWP.
SAFETY PROFILE. Levosimendan was tolerated well by this
population of relatively sick patients. As was anticipated,
vasodilatory reactions (headache, hypotension, dizziness and
nausea) were the most frequently observed adverse events in
patients receiving levosimendan or dobutamine. The in-
crease in HR observed during infusion of levosimendan was
associated with a reciprocal decrease in the uncorrected QT
interval. When the QT interval was corrected for changes in
HR using the Bazett formula (23), the aggregate effect of all
levosimendan doses was a slight increase in QTc (9 ms
compared with 21 ms with placebo and no change with
dobutamine). Examination of a large database of electro-
physiology recordings accrued with levosimendan has pro-
duced no evidence that the drug promotes clinically relevant
arrhythmia or disturbances in cardiac conduction pathways
at the doses recommended on the basis of observations in
this study (24). There was no evidence that levosimendan
exacerbated existing cardiac ischemia, a finding consistentTa
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with other data indicating that the effects of levosimendan
on myocardial performance are energy neutral (25), as well
as providing assurance that vasodilatation caused by levosi-
mendan does not compromise myocardial perfusion.
STUDY LIMITATIONS. Efforts were made to minimize he-
modynamic variability among patients in order to facilitate
precise examination of dose-response relationships. Thus,
patients were required to have been clinically stable for 1
month and to be receiving standardized medications for
CHF. The initial eligibility criteria resulted, however, in the
recruitment of patients with low PCWP. The protocol was
therefore amended to permit the recruitment of patients
with NYHA class IV. In addition, the left ventricular
ejection fraction criterion was lowered to ,35%. There is no
reason to believe that the dose-finding results of the current
study are not applicable to patients with more severe pump
failure, but an explicit proof of this assumption is desirable.
Patients received their assigned doses of the study med-
ication without uptitration. This fulfills the requirements of
a dose-response study but does not represent the clinical
situation in which therapy with a positive inotropic drug
would normally be initiated at low dose and titrated until
the desired effects were achieved. The present trial provides
little information about the feasibility or safety of uptitration
of levosimendan. Conversely, the study design permitted
dose reductions: this reflects clinical practice and ensured
patient safety. Dose reductions complicated the analysis of
dose-responsiveness, however, and may have concealed the
magnitude of the treatment effect on those parameters that
were used to mandate dose adjustment.
Despite these limitations, the results of this study clearly
demonstrate that intravenous administration of levosimen-
dan for 24 h produces favorable dose-dependent hemody-
namic effects in Caucasian male patients with stable
moderate-to-severe CHF, and defines the tolerated dose
range for this agent i.e., preferred starting dose of a bolus of
6 to 24 mg/kg in 10 min followed by infusion rates of 0.05
to 0.2 mg/kg/min.
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